Get started
Author

Wolfgang W. Wicha

Observed names: W. W. Wicha, WOLFGANG WICHA, Wolfgang W Wicha, Wolfgang Wicha
Observed institution: Nabriva Therapeutics (Austria)
ORCID: 0000-0002-4863-7559
Observed ORCID: 0000-0002-4863-7559
OpenAlex ID: A5011283999
Efficacy and Safety of Intravenous-to-oral Lefamulin, a Pleuromutilin Antibiotic, for the Treatment of Community-acquired Bacterial Pneumonia: The Phase III Lefamulin Evaluation Against Pneumonia (LEAP 1) Trial
2019 · Thomas M File, Lisa Goldberg, et al. · Clinical Infectious Diseases · 149
Oral Lefamulin vs Moxifloxacin for Early Clinical Response Among Adults With Community-Acquired Bacterial Pneumonia: The LEAP 2 Randomized Clinical Trial
2019 · Elizabeth Alexander, Lisa Goldberg, et al. · JAMA · 117
PDF
Erratum to: Efficacy and Safety of Intravenous-to-oral Lefamulin, a Pleuromutilin Antibiotic, for the Treatment of Community-acquired Bacterial Pneumonia: The Phase III Lefamulin Evaluation Against Pneumonia (LEAP 1) Trial
2019 · Thomas M File, Lisa Goldberg, et al. · Clinical Infectious Diseases · 77
PDF
Simultaneous assessment of the pharmacokinetics of a pleuromutilin, lefamulin, in plasma, soft tissues and pulmonary epithelial lining fluid
2016 · M. Zeitlinger, R. Schwameis, et al. · Journal of Antimicrobial Chemotherapy · 70
Pharmacokinetics/pharmacodynamics of lefamulin in a neutropenic murine pneumonia model withStaphylococcus aureusandStreptococcus pneumoniae
2019 · Wolfgang W Wicha, Dirk B Strickmann, et al. · Journal of Antimicrobial Chemotherapy · 40
In vivo pharmacodynamics of lefamulin, the first systemic pleuromutilin for human use, in a neutropenic murine thigh infection model
2019 · Wolfgang W Wicha, William A Craig, et al. · Journal of Antimicrobial Chemotherapy · 31
PDF
Population Pharmacokinetic Analyses for BC-3781 Using Phase 2 Data from Patients with Acute Bacterial Skin and Skin Structure Infections
2014 · C. M. Rubino, B. Xue, et al. · Antimicrobial Agents and Chemotherapy · 31
Pharmacokinetic/pharmacodynamic target attainment analyses to support intravenous and oral lefamulin dose selection for the treatment of patients with community-acquired bacterial pneumonia
2019 · Sujata M Bhavnani, Li Zhang, et al. · Journal of Antimicrobial Chemotherapy · 30
Pharmacokinetics and tolerability of lefamulin following intravenous and oral dosing
2019 · Wolfgang W Wicha, William T Prince, et al. · Journal of Antimicrobial Chemotherapy · 29
PDF
Pharmacodynamic evaluation of lefamulin in the treatment of gonorrhea using a hollow fiber infection model simulating Neisseria gonorrhoeae infections
2022 · Susanne Jacobsson, Daniel Golparian, et al. · Frontiers in Pharmacology · 27
Prediction of lefamulin epithelial lining fluid penetration after intravenous and oral administration using Phase 1 data and population pharmacokinetics methods
2019 · Li Zhang, Wolfgang W Wicha, et al. · Journal of Antimicrobial Chemotherapy · 20
Pharmacokinetics and safety of lefamulin after single intravenous dose administration in subjects with impaired renal function and those requiring hemodialysis
2021 · Wolfgang W. Wicha, Thomas C. Marbury, et al. · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · 10
LB6. Oral Lefamulin Is Safe and Effective in the Treatment of Adults With Community-Acquired Bacterial Pneumonia (CABP): Results of Lefamulin Evaluation Against Pneumonia (LEAP 2) Study
2018 · Elizabeth Alexander, Lisa Goldberg, et al. · Open Forum Infectious Diseases · 10
Anti-inflammatory activity of lefamulin versus azithromycin and dexamethasone in vivo and in vitro in a lipopolysaccharide-induced lung neutrophilia mouse model
2021 · Michael Hafner, Susanne Paukner, et al. · PLoS ONE · 9
PDF
Pharmacokinetics and safety of lefamulin after single intravenous dose administration in subjects with impaired‐hepatic function
2021 · Wolfgang W. Wicha, Thomas C. Marbury, et al. · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · 8
In Vivo Immune-Modulatory Activity of Lefamulin in an Influenza Virus A (H1N1) Infection Model in Mice
2024 · Susanne Paukner, Sandra Kimber, et al. · International Journal of Molecular Sciences · 5
Tissue Distribution of [ 14 C]-Lefamulin into the Urogenital Tract in Rats
2022 · Wolfgang W. Wicha, Claire Henson, et al. · Antimicrobial Agents and Chemotherapy · 5
Efficacy of Lefamulin Against Staphylococcus aureus-Induced Bacteremia in a Neutropenic and Immunocompetent Murine Model
2017 · Evelin Fischer, Barbara C Kappes, et al. · Open Forum Infectious Diseases · 5
Physiologically‐based pharmacokinetic modeling of the drug–drug interaction between ivacaftor and lefamulin in cystic fibrosis patients
2024 · Magali Amiel, Alice Ke, et al. · CPT Pharmacometrics & Systems Pharmacology · 3
PDF
Safety and Pharmacokinetics Following Oral or Intravenous Lefamulin in Adults With Cystic Fibrosis
2024 · Gregory S. Sawicki, Wolfgang W. Wicha, et al. · Clinical Therapeutics · 3
Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment (TA) Analyses Supporting Lefamulin Dose Selection for the Treatment of Patients With Community-Acquired Bacterial Pneumonia (CABP)
2015 · Sujata M. Bhavnani, Paul G. Ambrose, et al. · Open Forum Infectious Diseases · 3
2189. Anti-inflammatory Activity of Lefamulin in a Mouse Model of Influenza Virus H1N1 Infection
2022 · Wolfgang W Wicha, Sandy Kimber, et al. · Open Forum Infectious Diseases · 2
PDF
705. Pharmacokinetics (PK) and Safety of Lefamulin (LEF) After Single Intravenous Dose Administration in Subjects With Impaired Renal Function and in Those Requiring Hemodialysis
2019 · Wolfgang Wicha, Thomas C Marbury, et al. · Open Forum Infectious Diseases · 2
PDF
Population Pharmacokinetic (PPK) Analysis for Lefamulin Using Phase 1 Data and Assessment of Optimal PK Sampling Strategies (OSS) for a Phase 3 Community-Acquired Bacterial Pneumonia (CABP) Study
2016 · Li Zhang, Sujata M. Bhavnani, et al. · Open Forum Infectious Diseases · 2
PDF
Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Oral Lefamulin Dose Selection in the Treatment of Patients with Community-Acquired Bacterial Pneumonia (CABP)
2016 · Sujata M. Bhavnani, Li Zhang, et al. · Open Forum Infectious Diseases · 2
Works count: 28
Citation count: 691
H-index: 11
I10-index: 13
Year
Topic
Type